Theodora Hatziioannou
#106,063
Most Influential Person Now
Researcher
Theodora Hatziioannou's AcademicInfluence.com Rankings
Theodora Hatziioannoucomputer-science Degrees
Computer Science
#10687
World Rank
#11238
Historical Rank
Computational Linguistics
#2687
World Rank
#2716
Historical Rank
Machine Learning
#4871
World Rank
#4928
Historical Rank
Artificial Intelligence
#5239
World Rank
#5310
Historical Rank
Download Badge
Computer Science
Why Is Theodora Hatziioannou Influential?
(Suggest an Edit or Addition)According to Wikipedia, Theodora Hatziioannou is a Greek-American virologist. She known for her work discovering restriction factors that counteract HIV-AIDS and other primate lentiviruses, thus restricting them to specific species, and making it hard to study HIV-1 in animals. Her findings allowed her to develop the first HIV-1-based virus which is capable of recapitulating AIDS-like symptoms in a non-hominid . She is a Research Associate Professor in the Laboratory of Retrovirology at The Rockefeller University in New York. She is a co-author of a textbook on virology, Principles of Virology.
Theodora Hatziioannou's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals (2020) (1577)
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry (2007) (1282)
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants (2020) (915)
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) (831)
- Evolution of antibody immunity to SARS-CoV-2 (2021) (703)
- Evolution of Antibody Immunity to SARS-CoV-2 (2020) (680)
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) (621)
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants (2021) (520)
- Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) (471)
- MX2 is an interferon-induced inhibitor of HIV-1 infection (2013) (432)
- Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. (2009) (426)
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies (2020) (418)
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants (2020) (417)
- Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors (2003) (403)
- Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin (2008) (399)
- Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies (2020) (394)
- Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. (2004) (390)
- Nef proteins from simian immunodeficiency viruses are tetherin antagonists. (2009) (361)
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses (2020) (351)
- Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants (2009) (321)
- Enhanced SARS-CoV-2 neutralization by dimeric IgA (2020) (301)
- Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism (2002) (294)
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant (2021) (292)
- Animal models for HIV/AIDS research (2012) (281)
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses (2020) (262)
- Human Tripartite Motif 5α Domains Responsible for Retrovirus Restriction Activity and Specificity (2005) (258)
- Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies (2021) (239)
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo (2020) (236)
- Restriction of multiple divergent retroviruses by Lv1 and Ref1 (2003) (233)
- Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells (2005) (212)
- Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species (2008) (199)
- Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination (2021) (183)
- Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques (2016) (174)
- Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations (2021) (170)
- Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion (2006) (166)
- Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity (2005) (163)
- A macaque model of HIV-1 infection (2009) (163)
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape (2021) (159)
- Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals (2020) (148)
- Antiretroviral potential of human tripartite motif-5 and related proteins. (2006) (134)
- Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. (2020) (128)
- Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid (2004) (127)
- Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients (2020) (123)
- Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients (2020) (113)
- Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost (2022) (110)
- Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection (2002) (109)
- Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants (2021) (109)
- Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions (2004) (95)
- HIV/AIDS: in search of an animal model. (2007) (90)
- Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells (2007) (86)
- SIV Nef Proteins Recruit the AP-2 Complex to Antagonize Tetherin and Facilitate Virion Release (2011) (76)
- HIV-1–induced AIDS in monkeys (2014) (75)
- Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice (2021) (75)
- Plasma neutralization properties of the SARS-CoV-2 Omicron variant (2021) (72)
- Infection of Nondividing Cells by Rous Sarcoma Virus (2001) (71)
- Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents (2020) (70)
- Antiretroviral Activity and Vif Sensitivity of Rhesus Macaque APOBEC3 Proteins (2007) (64)
- Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. (1999) (62)
- Incorporation of Fowl Plague Virus Hemagglutinin into Murine Leukemia Virus Particles and Analysis of the Infectivity of the Pseudotyped Retroviruses (1998) (54)
- Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins (2022) (50)
- Primate Lentivirus Capsid Sensitivity to TRIM5 Proteins (2008) (49)
- Capsid-Dependent and -Independent Postentry Restriction of Primate Lentivirus Tropism in Rodent Cells (2004) (48)
- Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo (2016) (48)
- Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. (2014) (47)
- Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity (2020) (45)
- Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies (2021) (45)
- APOBEC3H structure reveals an unusual mechanism of interaction with duplex RNA (2017) (42)
- Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients (2020) (42)
- Receptor co‐operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding (1997) (41)
- Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection (2020) (40)
- Serological Analysis of New York City COVID19 Convalescent Plasma Donors (2020) (40)
- No effect of endogenous TRIM5α on HIV-1 production (2008) (39)
- Predictors of Nonseroconversion after SARS-CoV-2 Infection (2021) (38)
- Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies (2021) (38)
- Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies (2021) (38)
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals (2020) (35)
- Antiretroviral restriction factors. (2011) (35)
- Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro (2020) (35)
- Assisted Evolution Enables HIV-1 to Overcome a High TRIM5α-Imposed Genetic Barrier to Rhesus Macaque Tropism (2013) (34)
- Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection (2020) (34)
- Overexpression of fasciculation and elongation protein zeta-1 (FEZ1) induces a post-entry block to retroviruses in cultured cells. (2005) (34)
- Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies (2021) (33)
- Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses (2013) (33)
- Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose (2022) (32)
- Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo (2020) (30)
- Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells (2005) (30)
- Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape (2021) (28)
- Replication and single-cycle delivery of SARS-CoV-2 replicons (2021) (28)
- Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations (2021) (27)
- A single gp120 residue can affect HIV-1 tropism in macaques (2017) (22)
- Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans (2022) (21)
- Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency (2020) (19)
- Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection (2021) (17)
- Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins (2022) (16)
- Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes (2019) (14)
- Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. (2021) (14)
- High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies (2021) (13)
- Erratum: Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding (The EMBO Journal (1997) 16 (1214-1223)) (1997) (13)
- Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques (2021) (12)
- Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants (2021) (12)
- Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination (2022) (11)
- Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity (2021) (10)
- Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 (2021) (10)
- ICTV Virus Taxonomy Profile: Retroviridae 2021 (2021) (9)
- Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens (2022) (9)
- Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity (2019) (9)
- Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host (2019) (9)
- Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape (2022) (8)
- Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans (2022) (7)
- Antibody and memory B-cell immunity in a heterogeneously SARS-CoV-2 infected and vaccinated population (2022) (7)
- Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis (2022) (6)
- Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination (2022) (6)
- Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection (2019) (6)
- “A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.” (2020) (5)
- Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies (2021) (4)
- Incorporation of simian virus 5 fusion protein into murine leukemia virus particles and its effect on the co-incorporation of retroviral envelope glycoproteins. (2000) (4)
- Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain (2022) (3)
- Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease (2021) (3)
- Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection (2022) (3)
- Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease (2021) (3)
- Molecular modelling predicts SARS-CoV-2 ORF8 protein and human complement Factor 1 catalytic domain sharing common binding site on complement C3b (2020) (3)
- SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection (2022) (2)
- Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population (2022) (2)
- Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants (2022) (2)
- Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting (2021) (2)
- Identification of claudin-1 as an essential cellular cell entry factor for hepatitis C virus (2006) (2)
- Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland (2021) (1)
- A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques. (2021) (1)
- Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. (2019) (0)
- APOBEC3H structure reveals an unusual mechanism of interaction with duplex RNA (2017) (0)
- Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain (2023) (0)
- Crystal Structure of macaque APOBEC3H in complex with RNA (2017) (0)
- Human Tripartite Motif 5 (cid:2) Domains Responsible for Retrovirus Restriction Activity and Specificity (2005) (0)
- Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral Immunodeficiency (2020) (0)
- Publisher Correction: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice (2021) (0)
- Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape (2023) (0)
- Receptor co‐operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding (0)
- Host Resistance to Retroviruses (2008) (0)
- Correction for Bitzegeio et al., Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses (2015) (0)
- Author response: Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape (2021) (0)
- 689. Restriction Profiles of Primate TRIM5α on FIV (2006) (0)
- Author response: Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection (2019) (0)
This paper list is powered by the following services:
Other Resources About Theodora Hatziioannou
What Schools Are Affiliated With Theodora Hatziioannou?
Theodora Hatziioannou is affiliated with the following schools:
